Cite

    Yoshida, S. et al. (2021). Can progressive site‐directed therapy prolong the efficacy of subsequent androgen receptor axis‐targeted drugs in oligometastatic castration‐resistant prostate cancer?. International journal of urology. pp. 241-242. [Online].